Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-14.08M | $-56.00 |
| 2024 | $582.0K | $-44.54M | $-39.25 |
| 2023 | $68.0K | $-21.67M | $-102.00 |
| 2022 | $0.00 | $-24.58M | $-201.50 |
| 2021 | $0.00 | $-122.55M | $-1415.25 |
Social Signal Score
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $-3.84 per share
Typical surprise +46.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-3.40 vs $-3.30miss
- Mon, May 11$-6.95 vs $-1.95miss
- Fri, Nov 7$-0.15 vs $-33.00beat
- Wed, Aug 13$-0.61 vs $-39.00beat
- Wed, May 7$-2.25 vs $-48.00beat
- Thu, Mar 13$-48.00 vs $-37.50miss
Estimates and results for ERNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ERNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·5d ago·Neutral
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
View source ↗